The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
time to resolution
Timeframe: 24hrs, and then weekly, after insertion
percentage requiring dilation and curettage
Timeframe: 24hrs, and then weekly, after insertion
failure to expel products of conception
Timeframe: 24hrs, and then weekly, after insertion
change in hematocrit
Timeframe: 24hrs, and then weekly, after insertion
side effects
Timeframe: 24hrs, and then weekly, after insertion
BHCG level
Timeframe: 24hrs, and then weekly, after insertion